Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Dosimetry-based treatment for Graves' disease.

Hyer SL, Pratt B, Gray M, Chittenden S, Du Y, Harmer CL, Flux GD.

Nucl Med Commun. 2018 Jun;39(6):486-492. doi: 10.1097/MNM.0000000000000826.

2.

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD.

Nucl Med Commun. 2016 May;37(5):466-72. doi: 10.1097/MNM.0000000000000470.

3.

Patient-specific dosimetry for intracavitary 32P-chromic phosphate colloid therapy of cystic brain tumours.

Denis-Bacelar AM, Romanchikova M, Chittenden S, Saran FH, Mandeville H, Du Y, Flux GD.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1532-41. doi: 10.1007/s00259-013-2451-6. Epub 2013 Jun 6.

PMID:
23740370
4.

Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.

Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD.

Nucl Med Commun. 2012 Jul;33(7):726-32. doi: 10.1097/MNM.0b013e328353bb6e.

PMID:
22513884
5.

Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.

Hindorf C, Chittenden S, Causer L, Lewington VJ, M├Ącke HR, Flux GD.

Cancer Biother Radiopharm. 2007 Feb;22(1):130-5.

PMID:
17627421
6.

Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used.

Divoli A, Bloch G, Chittenden S, Malaroda A, O'Sullivan JM, Dearnaley DP, Flux GD.

Cancer Biother Radiopharm. 2007 Feb;22(1):121-4.

PMID:
17627420
7.

Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.

Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, Flux GD.

Cancer Biother Radiopharm. 2007 Feb;22(1):105-12.

PMID:
17627418
8.

Preparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy.

Courbon F, Love P, Chittenden S, Flux G, Ravel P, Cook G.

Cancer Biother Radiopharm. 2006 Oct;21(5):427-36.

PMID:
17105417
9.

Whole-body dosimetry for targeted radionuclide therapy using spectral analysis.

Divoli A, Spinelli A, Chittenden S, Dearnaley D, Flux G.

Cancer Biother Radiopharm. 2005 Feb;20(1):66-71.

PMID:
15778583
10.

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.

O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, Guy M, Pomeroy K, Cook G, Gadd J, Treleaven J, Al-Deen A, Horwich A, Huddart RA, Dearnaley DP.

Br J Cancer. 2002 Jun 5;86(11):1715-20.

11.

Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with (131)I.

Hammersley PA, Al-Saadi A, Chittenden S, Flux GD, McCready VR, Harmer CL.

Br J Radiol. 2001 May;74(881):429-33.

PMID:
11388991
12.

Microvascular vasodilatation in non-insulin dependent diabetes.

Shami SK, Chittenden S, Sarin S.

BMJ. 1991 Jun 15;302(6790):1465. No abstract available.

Supplemental Content

Loading ...
Support Center